Related Experiment Video

Updated: May 13, 2026

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
09:04

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids

Published on: September 21, 2017

Mini-review: nucleus-targeted ribonucleases as antitumor drugs

J Castro1, M Ribó, A Benito

  • 1Laboratori d'Enginyeria de Proteïnes, Departament de Biologia, Facultat de Ciències, Universitat de Girona, Maria Aurèlia Capmany, 69, Campus de Montilivi s/n E-17071 Girona, Spain.

Current Medicinal Chemistry
|February 26, 2013
PubMed

Insights

New nuclear-targeted drugs, including ribonucleases, offer a promising strategy against cancer. This approach aims for more efficient and selective antitumor effects, potentially overcoming drug resistance mechanisms.

Area of Science:

  • Oncology
  • Drug Discovery
  • Molecular Biology

Background:

  • Cancer represents a significant global health burden, increasing with population aging.
  • Current cancer therapies require more efficient and selective antitumor drugs.
  • Drug resistance remains a challenge in cancer treatment.

Purpose of the Study:

  • To review the potential of nuclear-targeted drugs as antineoplastic therapeutics.
  • To explore the benefits of using ribonucleases with cytotoxic properties for cancer treatment.
  • To highlight strategies for developing novel anticancer agents.

Main Methods:

  • Literature review on nuclear-targeted drug strategies.
  • Analysis of pleiotropic non-genotoxic effectors in cancer therapy.
  • Discussion of ribonucleases as potential cytotoxic agents for nuclear delivery.

Main Results:

  • Nuclear targeting enhances drug efficiency and selectivity against cancer cells.
  • Non-genotoxic agents may circumvent known drug resistance mechanisms.
  • Ribonucleases show potential for targeted cancer cell killing upon nuclear delivery.

Conclusions:

  • Nuclear-targeted drugs represent a promising strategy for improved cancer treatment.
  • Endowing ribonucleases with cytotoxic properties and nuclear targeting could lead to novel anticancer therapies.
  • This approach offers a potential solution to overcome drug resistance in oncology.

More Related Videos

NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases10:24

NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases

Published on: June 30, 2019

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Related Concept Videos

The Nucleolus02:55

The Nucleolus

The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Ribozymes02:47

Ribozymes

The term ribozyme is used for RNA that can act as an enzyme. Ribozymes are mainly found in selected viruses, bacteria, plant organelles, and lower eukaryotes. Ribozymes were first discovered in 1982 when Tom Cech’s laboratory observed Group I introns acting as enzymes. This was shortly followed by the discovery of another ribozyme, Ribonulcease P, by Sid Altman’s laboratory. Both Cech and Altman received the Nobel Prize in chemistry in 1989 for their work on ribozymes.
Ribozymes can be...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...